Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Human Metapneumovirus (hMPV) Therapeutics Market Size Forecast: How Big Could The Market Get By 2030?
The human metapneumovirus (hmpv) therapeutics market has seen robust expansion in its size over recent years. This market is projected to expand from $0.7 billion in 2025 to $0.74 billion by 2026, exhibiting a compound annual growth rate (CAGR) of 6.2%. Historically, this growth has been driven by several factors, including the widespread occurrence of respiratory viral infections, the absence of specific approved antiviral treatments for hmpv, a dependence on supportive and symptomatic care methods, a rise in hospital admissions for infants and elderly patients, and increasing understanding of viral lower respiratory tract infections.
The market for human metapneumovirus (hmpv) therapeutics is projected to experience substantial expansion over the coming years, reaching a valuation of $0.94 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.0%. This anticipated growth during the forecast period is driven by several factors, including an increased emphasis on developing therapeutics specifically targeting the virus, a rise in investment dedicated to respiratory virus research, a growing need for effective treatments among immunocompromised individuals, the expansion of clinical trials for new antiviral agents, and enhanced readiness for seasonal respiratory virus epidemics. Key trends anticipated within this forecast timeframe involve a heightened focus on antiviral therapies specifically designed for respiratory viruses, an escalating requirement for symptom-focused management in both pediatric and geriatric patient groups, a greater emphasis on early intervention strategies for at-risk populations, the broadening of supportive care treatments for viral respiratory infections, and an uptick in clinical research exploring new hmpv treatment possibilities.
Get A Free Sample Report With In-Depth Market Insights:
Human Metapneumovirus (hMPV) Therapeutics Market Growth Catalysts And Demand Drivers
The rising occurrence of respiratory infections is anticipated to boost the expansion of the human metapneumovirus (HMPV) therapeutics market in the future. These infections are conditions impacting the respiratory tract, encompassing the nose, throat, airways, and lungs. The growing incidence of respiratory infections stems from elevated levels of air pollution. Contaminants such as particulate matter and nitrogen dioxide irritate and compromise the respiratory tract, thereby increasing individuals’ vulnerability to infections. Human metapneumovirus (hMPV) therapeutics play a crucial role in managing respiratory infections brought on by hMPV; they achieve this by mitigating viral replication and inflammation via antiviral therapies and supportive interventions, leading to better health outcomes for susceptible populations like infants, the elderly, and immunocompromised individuals. As an illustration, in June 2024, the Australian Institute of Health and Welfare, an Australia-based government agency, reported that Chronic Obstructive Pulmonary Disease (COPD) in Australia was responsible for 3.6% of the overall disease burden in 2023. This condition represented 50% of the total burden from respiratory ailments, with approximately 638,000 people (2.5% of the population) affected by COPD in 2022. Consequently, the rising prevalence of respiratory infections fuels the expansion within the human metapneumovirus (HMPV) therapeutics market.
Human Metapneumovirus (hMPV) Therapeutics Market Segment Analysis Spotlighting Growth Areas
The human metapneumovirus (hmpv) therapeutics market covered in this report is segmented –
1) By Drug Class: Antipyretic, Decongestants, Cough Suppressants, Other Drug Classes
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By End-Use: Hospitals And Clinics, Academic And Research Institutions, Other End-Uses
Subsegments:
1) By Antipyretic: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Acetaminophen (Paracetamol)
2) By Decongestants: Nasal Decongestants, Oral Decongestants
3) By Cough Suppressants: Dextromethorphan, Benzonatate
4) By Other Drug Classes: Antiviral Agents, Inhaled Corticosteroids
Human Metapneumovirus (hMPV) Therapeutics Market Trends Shaping Long-Term Demand
In the human metapneumovirus (hMPV) therapeutics market, leading companies are concentrating on developing specific antiviral treatments, including monoclonal antibodies, to effectively combat hMPV infections. Monoclonal antibodies (mAbs) are laboratory-manufactured proteins designed to mimic the immune system’s natural ability to combat diseases. These antibodies offer targeted therapeutic approaches for various conditions, such as cancer and autoimmune disorders, by specifically binding to and neutralizing harmful antigens or cells. For instance, in October 2024, Vicebio Ltd., a biopharmaceutical company based in the UK, successfully secured $100 million in Series B financing, led by TCGX with participation from Goldman Sachs Alternatives and other investors, to advance its next-generation respiratory virus vaccines. This funding is allocated to support the Phase 1 clinical trial of VXB-241, a bivalent vaccine targeting both RSV and hMPV, with initial results projected for mid-2025. Furthermore, it will accelerate the development of VXB-251, a trivalent vaccine aimed at RSV, hMPV, and Parainfluenza Virus 3, intended to address substantial medical challenges faced by older individuals.
Human Metapneumovirus (hMPV) Therapeutics Market Leading Companies: Who Holds The Strongest Market Presence?
Major companies operating in the human metapneumovirus (hmpv) therapeutics market are Pfizer Inc., Sanofi S.A, AstraZeneca Plc, Merck KGaA, Moderna Inc, Novartis AG, Roche Holding AG, Johnson & Johnson, GlaxoSmithKline plc, Eli Lilly and Company, Bristol Myers Squibb Company, AbbVie Inc, Takeda Pharmaceutical Company Limited, Bayer AG, CSL Limited, Regeneron Pharmaceuticals Inc, BioNTech SE, Vertex Pharmaceuticals Incorporated, Alnylam Pharmaceuticals Inc, Vir Biotechnology Inc., Enanta Pharmaceuticals Inc.
View The Full Human Metapneumovirus (hMPV) Therapeutics Market Report:
Human Metapneumovirus (hMPV) Therapeutics Market Top Region: Where Does Most Revenue Come From?
North America was the largest region in the human metapneumovirus (hMPV) therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human metapneumovirus (hmpv) therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
